Risk of Serious Infections in Patients Treated With Biologic or Targeted‐synthetic Disease Modifying Antirheumatic Drugs in Qatar

Risk of Serious Infections in Patients Treated With Biologic or Targeted‐synthetic Disease Modifying Antirheumatic Drugs in Qatar

<h3>Background</h3><p dir="ltr">Biologic and targeted‐synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs), are pivotal in the management of autoimmune‐inflammatory disorders, acting by suppressing pathological immune activation. Because of associated immune dysfu...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Sreethish Sasi (14151873) (author)
مؤلفون آخرون: Hamad Abdel Hadi (11819159) (author), Masautso Chaponda (22466563) (author), Reem El Ajez (22466566) (author), Mohamed Ataelmanan (22466569) (author), Sief Khasawneh (22466572) (author), Hind Saqallah (22466575) (author), Maisa Ali (4808649) (author), Nabeel Abdulla (21406769) (author), Javed Iqbal (2121922) (author), Ali S. Omrani (9590116) (author), Muna Al Maslamani (12501671) (author), Abdullatif Al‐Khal (14779372) (author)
منشور في: 2025
الموضوعات:
Biomedical and clinical sciences
Immunology
Pharmacology and pharmaceutical sciences
Health sciences
Epidemiology
biologic
DMARD
immunocompromised
TNF‐alpha inhibitor
tofacitinib
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

مواد مشابهة